The coronavirus variant discovered in SA may evade the protection provided by Pfizer/BioNTech's Covid-19 vaccine to some extent, a real-world data study in Israel has found, though its prevalence in the country is very low and the research has not been peer reviewed. According to Timeslive, the study compared almost 400 people who had tested positive for Covid-19, 14 days or more after they received one or two doses of the vaccine, against the same number of unvaccinated patients with the disease. - Smile 90.4FM

The coronavirus variant discovered in SA may evade the protection provided by Pfizer/BioNTech’s Covid-19 vaccine to some extent, a real-world data study in Israel has found, though its prevalence in the country is very low and the research has not been peer reviewed. According to Timeslive, the study compared almost 400 people who had tested positive for Covid-19, 14 days or more after they received one or two doses of the vaccine, against the same number of unvaccinated patients with the disease.